API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Highest Development Status: Phase I
Therapeutic Area: Endocrinology
Interventions: Exenatide
Product Type: Large molecule
Sponsor: Oramed Inc
Receptors: Glucagon-like peptide 1 recept...
Trial ID: NA
Location: NA
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Capsule
Collaborator: NA
Recruitment Status: NA
Date Of Registration: NA
Product Description: ORMD-0901 (Exenatide), a GLP-1 analog, is based on Oramed
Highest Development Status: Undisclosed
Therapeutic Area: Endocrinology
Interventions: Exenatide,Insulin
Product Type: Large molecule
Sponsor: Oramed Inc
Receptors: Insulin receptor agonist||Gluc...
Trial ID: NA
Location: NA
Condition: Type 2 diabetes mellitus
Product Status: Approved
Dosage Form: Oral
Collaborator: NA
Recruitment Status: NA
Date Of Registration: NA
Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.